Personalization of thiopurine therapy: Current recommendations and future perspectives
Despite great therapeutic advances in the field of biologics, small synthetic molecules such as thiopurines, including azathioprine, mercaptopurine, and thioguanine, remain an important therapeutic pillar in the treatment of inflammatory bowel disease, other autoimmune disorders, and cancer. This re...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2024-09-01
|
| Series: | Acta Pharmaceutica |
| Subjects: | |
| Online Access: | https://doi.org/10.2478/acph-2024-0030 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832572719970910208 |
|---|---|
| author | Urbančič Dunja Pasha Flaka Šmid Alenka Mlinarič-Raščan Irena |
| author_facet | Urbančič Dunja Pasha Flaka Šmid Alenka Mlinarič-Raščan Irena |
| author_sort | Urbančič Dunja |
| collection | DOAJ |
| description | Despite great therapeutic advances in the field of biologics, small synthetic molecules such as thiopurines, including azathioprine, mercaptopurine, and thioguanine, remain an important therapeutic pillar in the treatment of inflammatory bowel disease, other autoimmune disorders, and cancer. This review presents the latest guidelines for thiopurine administration, highlighting the importance of individualized therapy guided by pharmacogenomics. It emphasizes dose adjustment based on nudix hydrolase 15 (NUDT15) and thiopurine S-methyltransferase (TPMT) genotype, along side thiopurine S-methyltransferase activity and thiopurine metabolic profile. In addition, the article takes a critical look at emerging research in the field of thiopurine pharmaco genomics featuring novel genetic markers and technological developments in genetic testing. Finally, the potential of integrated approaches that combine genetic, meta bolic, and clinical factors to further individualize thiopurine therapy is highlighted. |
| format | Article |
| id | doaj-art-dc46147608ac49e483c3a232907cf544 |
| institution | Kabale University |
| issn | 1846-9558 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | Sciendo |
| record_format | Article |
| series | Acta Pharmaceutica |
| spelling | doaj-art-dc46147608ac49e483c3a232907cf5442025-02-02T08:34:38ZengSciendoActa Pharmaceutica1846-95582024-09-0174335538110.2478/acph-2024-0030Personalization of thiopurine therapy: Current recommendations and future perspectivesUrbančič Dunja0Pasha Flaka1Šmid Alenka2Mlinarič-Raščan Irena3University of Ljubljana, Faculty of Pharmacy, 1000Ljubljana, SloveniaUniversity of Ljubljana, Faculty of Pharmacy, 1000Ljubljana, SloveniaUniversity of Ljubljana, Faculty of Pharmacy, 1000Ljubljana, SloveniaUniversity of Ljubljana, Faculty of Pharmacy, 1000Ljubljana, SloveniaDespite great therapeutic advances in the field of biologics, small synthetic molecules such as thiopurines, including azathioprine, mercaptopurine, and thioguanine, remain an important therapeutic pillar in the treatment of inflammatory bowel disease, other autoimmune disorders, and cancer. This review presents the latest guidelines for thiopurine administration, highlighting the importance of individualized therapy guided by pharmacogenomics. It emphasizes dose adjustment based on nudix hydrolase 15 (NUDT15) and thiopurine S-methyltransferase (TPMT) genotype, along side thiopurine S-methyltransferase activity and thiopurine metabolic profile. In addition, the article takes a critical look at emerging research in the field of thiopurine pharmaco genomics featuring novel genetic markers and technological developments in genetic testing. Finally, the potential of integrated approaches that combine genetic, meta bolic, and clinical factors to further individualize thiopurine therapy is highlighted.https://doi.org/10.2478/acph-2024-0030thiopurinestpmtnudt15personalized medicinetherapeutic drug monitoring |
| spellingShingle | Urbančič Dunja Pasha Flaka Šmid Alenka Mlinarič-Raščan Irena Personalization of thiopurine therapy: Current recommendations and future perspectives Acta Pharmaceutica thiopurines tpmt nudt15 personalized medicine therapeutic drug monitoring |
| title | Personalization of thiopurine therapy: Current recommendations and future perspectives |
| title_full | Personalization of thiopurine therapy: Current recommendations and future perspectives |
| title_fullStr | Personalization of thiopurine therapy: Current recommendations and future perspectives |
| title_full_unstemmed | Personalization of thiopurine therapy: Current recommendations and future perspectives |
| title_short | Personalization of thiopurine therapy: Current recommendations and future perspectives |
| title_sort | personalization of thiopurine therapy current recommendations and future perspectives |
| topic | thiopurines tpmt nudt15 personalized medicine therapeutic drug monitoring |
| url | https://doi.org/10.2478/acph-2024-0030 |
| work_keys_str_mv | AT urbancicdunja personalizationofthiopurinetherapycurrentrecommendationsandfutureperspectives AT pashaflaka personalizationofthiopurinetherapycurrentrecommendationsandfutureperspectives AT smidalenka personalizationofthiopurinetherapycurrentrecommendationsandfutureperspectives AT mlinaricrascanirena personalizationofthiopurinetherapycurrentrecommendationsandfutureperspectives |